Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
83 hedge funds and large institutions have $291M invested in Northwest Biotherapeutics, Inc. Common stock in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 8 reducing their positions, and 10 closing their positions.
375% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 8
125% more capital invested
Capital invested by funds: $129M → $291M (+$162M)
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
11% more funds holding
Funds holding: 75 → 83 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less call options, than puts
Call options by funds: $15.7M | Put options by funds: $24.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$64.3M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$8.21M |
| 3 |
Goldman Sachs
New York
|
+$7.27M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.95M |
| 5 |
CWM
CIBC World Markets
New York
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bolton LP
Greenwich,
Connecticut
|
-$369K |
| 2 |
JP Morgan Chase
New York
|
-$285K |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$141K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$119K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$106K |
NWBO Hedge Fund Activity: Q2 2015 in Review
83 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2015, worth a combined $291M — up 125% from $129M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NWBO positions and 10 closed out — a net gain of 9 holders — while 38 added to existing stakes and 8 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $64.3M. The largest seller was Bolton LP, exiting entirely with an estimated $369K sold.
- 83 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2015, up from 75 in Q1 2015.
- Funds reported $291M of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2015, up 125% quarter-over-quarter.
- 19 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2015 and 10 closed out, a net change of +9 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2015 was Woodford Investment Management, an estimated $64.3M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2015 was Bolton LP, an estimated $369K sold.
Based on aggregated 13F filings for Q2 2015.